Compare ODFL & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODFL | NTRA |
|---|---|---|
| Founded | 1934 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.7B | 32.9B |
| IPO Year | 1991 | 2015 |
| Metric | ODFL | NTRA |
|---|---|---|
| Price | $207.11 | $206.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 14 |
| Target Price | $166.84 | ★ $253.79 |
| AVG Volume (30 Days) | ★ 2.1M | 1.1M |
| Earning Date | 02-04-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.59% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.97 | N/A |
| Revenue | ★ $5,574,922,000.00 | $2,116,676,000.00 |
| Revenue This Year | N/A | $33.95 |
| Revenue Next Year | $2.41 | $16.72 |
| P/E Ratio | $38.20 | ★ N/A |
| Revenue Growth | N/A | ★ 38.17 |
| 52 Week Low | $126.01 | $125.38 |
| 52 Week High | $209.61 | $256.36 |
| Indicator | ODFL | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 81.63 | 26.35 |
| Support Level | $169.99 | $229.14 |
| Resistance Level | $175.79 | $236.58 |
| Average True Range (ATR) | 6.24 | 9.02 |
| MACD | 1.98 | -3.25 |
| Stochastic Oscillator | 99.11 | 1.51 |
Old Dominion Freight Line is the second-largest less-than-truckload carrier in the United States (following FedEx Freight), with more than 250 service centers and 11,000-plus tractors. It is one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns are head and shoulders above its peers. Strategic initiatives revolve around boosting network density through market share gains and maintaining industry-leading service (including ultralow cargo claims) via steadfast infrastructure investment.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.